Baird initiated coverage of Coherus Biosciences with an Outperform rating and $11 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences price target lowered to $11 from $14 at Citi
- Coherus Biosciences cut to Hold at Maxim on slow start for Yusimry
- Coherus Biosciences downgraded to Hold from Buy at Maxim
- Coherus Biosciences price target lowered to $12 from $20 at Truist
- Coherus Biosciences price target lowered to $13 from $20 at H.C. Wainwright